



ROQUIN/RC3H1 alterations are not found in angioimmunoblastic T-cell lymphoma.

Tiphanie Auguste, Marion Travert, Karin Tarte, Patricia Amé-Thomas,
Catherine Artchounin, Nadine Martin-Garcia, Aurélien de Reynies, Laurence
de Leval, Philippe Gaulard, Marie-Hélène Delfau-Larue

► To cite this version:

Tiphanie Auguste, Marion Travert, Karin Tarte, Patricia Amé-Thomas, Catherine Artchounin, et al..
ROQUIN/RC3H1 alterations are not found in angioimmunoblastic T-cell lymphoma.. PLoS ONE,
2013, 8 (6), pp.e64536. 10.1371/journal.pone.0064536 . inserm-00868981

HAL Id: inserm-00868981

<https://inserm.hal.science/inserm-00868981>

Submitted on 2 Oct 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ROQUIN/RC3H1 Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma

Tiphane Auguste^{1,2}, Marion Travert¹, Karin Tarte³, Patricia Amé-Thomas³, Catherine Artchounin^{1,6}, Nadine Martin-Garcia^{1,6}, Aurélien de Reynies⁴, Laurence de Leval⁵, Philippe Gaulard^{1,2,6}, Marie-Hélène Delfau-Larue^{1,2,7*}

1 INSERM U955, Immunologie et Oncogenèse des Tumeurs Lymphoïdes, Créteil, France, **2** Faculté de Médecine, Université Paris-Est, Créteil, France, **3** INSERM U917, Microenvironnement et Cancer, Rennes, France, **4** Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France, **5** Service de Pathologie Clinique, Institut Universitaire de Pathologie, Lausanne, Switzerland, **6** Département de Pathologie, Groupe Hospitalier Henri Mondor–Albert Chenevier, Créteil, France, **7** Laboratoire d'Immunologie Biologique, Assistance Publique–Hôpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier, Créteil, France

Abstract

Angioimmunoblastic T-cell Lymphoma (AITL) is one of the most frequent T-cell lymphoma entities. Follicular helper T lymphocytes (TFH) are recognized as the normal cellular counterpart of the neoplastic component. Despite a clonal T-cell feature and few described recurrent cytogenetic abnormalities, a driving oncogenic event has not been identified so far. It has been recently reported that in mice, heterozygous inactivation of *Roquin/Rc3h1*, a RING type E3 ubiquitin ligase, recapitulates many of the clinical, histological, and cellular features associated with human AITL. In this study we explored whether ROQUIN alterations could be an initial event in the human AITL oncogenic process. Using microarray and RT-PCR analyses, we investigated the levels of ROQUIN transcripts in TFH tumor cells purified from AITL (n = 8) and reactive tonsils (n = 12) and found similar levels of ROQUIN expression in both. Moreover, we also demonstrated that ROQUIN protein was expressed by AITL TFH (PD1+) cells. We then analysed ROQUIN coding sequence in 12 tumor cell-rich AITL samples and found no mutation in any of the samples. Finally, we analysed the expression of MiR101, a putative partner of ROQUIN involved in the modulation of ICOS expression and found similar levels of expression in tumor and reactive TFH. Altogether, this study shows that neither alteration of ROQUIN gene nor deregulation of miR101 expression is likely to be a frequent recurrent event in AITL.

Citation: Auguste T, Travert M, Tarte K, Amé-Thomas P, Artchounin C, et al. (2013) *ROQUIN/RC3H1* Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma. PLoS ONE 8(6): e64536. doi:10.1371/journal.pone.0064536

Editor: Paul J. Galaray, Mayo Clinic, United States of America

Received: September 19, 2012; **Accepted:** April 16, 2013; **Published:** June 25, 2013

Copyright: © 2013 Auguste et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut National du Cancer (INCA), the Fondation pour la Recherche Médicale (équipe FRM, FRM DEQ20100318253), the Plan Cancer (Belgium), the Association pour la Recherche Thérapeutique, Génétique et Immunologique dans les Lymphomes (ARTGIL). MT was supported by the FRM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: marie-helene.delfau@hmn.aphp.fr

Introduction

Angioimmunoblastic T-cell Lymphoma (AITL) is a distinct T-cell lymphoma entity [1] originally described as a dysimmune condition [2]. It usually manifests with generalized lymphadenopathy, hepatomegaly, splenomegaly, fever, sweats, and skin rash and is frequently associated with clinical and biological autoimmune manifestations [3]. A clonal T-Cell Receptor gene rearrangement is detected in around 80% of the cases [4,5], and few recurrent cytogenetic abnormalities have been reported (reviewed in [6]). Recently, we have reported mutations in isocitrate dehydrogenases 2 (IDH2) [7] and Ten-Eleven Translocation 2 (TET2) [8] genes in AITL, two genes involved in epigenetic gene regulation, but to date, no driving oncogenic event has been identified. We and others have shown that Follicular Helper T (TFH) cells are the normal cellular counterpart of the neoplastic component of AITL [9–12]. TFH cells constitute a specialized subset of T cells which allows the selection of high-affinity B lymphocytes within germinal centers and provide helper function for antibody production [13]. Human TFH cells express

high levels of BCL6, PD1, ICOS, the chemokine CXCL13 and its receptor (CXCR5) and secrete the cytokine IL-21 [14–18].

Recently, a mouse model has been proposed for AITL [19]. It recapitulates many of the clinical and pathological features associated with AITL, including lymphadenopathy, hypergammaglobulinemia and accumulation/expansion of clonal TFH cells. This phenotype is specifically linked to heterozygous *Roquin/Rc3h1* point mutation (sanroque allele) in T cells [20]. Roquin, a RING-type E3 ubiquitin ligase family member, has been previously identified as a regulator of autoimmune responses in mice [20].

We thus hypothesized that in human, *ROQUIN/RC3H1* alterations could occur as an initial event of the AITL oncogenic process, leading to TFH accumulation or proliferation prone to subsequent transforming events.

Material and Methods

The present study was approved by the institutional review board “Comité de Protection des Personnes, Créteil, France” (CPP 09–008). Written consent was obtained from patients with lymphoma. Reactive human tonsils were collected from children




Figure 1. Illustrative case of AITL rich in tumor cells. Diffuse proliferation of large neoplastic cells surrounded by inflammatory cells (plasma cells, eosinophils) and vascular hyperplasia (hematoxylin-eosin, original magnification $\times 20$) (A). Numerous neoplastic cells highlighted by positivity for T_{FH} markers CXCL13 (B), ICOS (C) and PD1 (D) (immunoperoxidase, original magnification $\times 20$). doi:10.1371/journal.pone.0064536.g001

undergoing routine tonsillectomy. Oral information was given to parents. A consent form attesting the oral consent was signed by the surgeon and given to the research team with tonsils.

Cell samples and AITL tissues

Normal cell subsets were isolated from reactive human tonsils. Briefly, mononuclear cells were isolated by mechanical disruption followed by Ficoll-hypaque density gradient centrifugation. T_{FH} cells were purified after depletion of CD19, CD8, CD14 and CD16-positive cells with magnetic beads (Milteny Biotec, Paris, France), by cell sorting of CD4-FITC, CXCR5-PE and ICOS-PC7 triple-positive cells on Mo-Flo legacy (Beckman Coulter, Villepinte, France). Tonsil CD4⁺, CD8⁺ T-cells and B-cells were purified by positive selection with antibodies directed against CD4, CD8, and CD19 respectively (Milteny Biotec, Paris, France). Neoplastic T_{FH} cells were isolated from cryopreserved mononuclear cell suspensions of AITL lymph node biopsies, through a one-step CD4-FITC, CXCR5-PE and ICOS-PC7 cell sorting.




Figure 2. ROQUIN expression in human reactive and tumoral lymphoid samples. Levels of *ROQUIN* transcripts determined by gene expression profiling of 17 AITL tumor tissue samples and 2 AITL cell suspensions enriched in tumor cells ($\geq 50\%$) samples as previously reported [10]. (probe-set 228996_at): *ROQUIN* transcripts level is slightly higher in enriched tumor cell sample ($P = 0.0067$ unpaired t-test) (A). *ROQUIN* mRNA levels determined by quantitative RT-PCR in reactive tonsils; total extract ($n = 1$), CD4⁺ ($n = 2$), CD8⁺ ($n = 2$), or CD19⁺ ($n = 2$) lymphocytes. Results were normalized by HPRT and compared to reactive purified TFH cells as calibrator: reactive CD4- CD8- and CD19-positive subsets display heterogeneous levels of *ROQUIN* mRNA (B). *ROQUIN* mRNA levels [(228996_at) probeset] in purified reactive ($n = 12$) and neoplastic T_{FH} cells ($n = 8$). T_{FH} cells were purified from 12 reactive tonsils and 8 AITL lymph nodes, RNA was extracted and whole genome expression was analysed on HG-U133 plus 2.0 Affymetrix GeneChip arrays. Similar levels of *ROQUIN* transcript are observed (C). doi:10.1371/journal.pone.0064536.g002




Figure 3. Immunohistochemical detection of ROQUIN in AITL. Among the many cells showing a cytoplasmic granular staining for ROQUIN (brown), a few are PAX5-positive large cells (B-immunoblasts) (pink arrow) whereas most of them are small to medium-sized PAX5-negative lymphoid cells forming small aggregates, corresponding to neoplastic cells of AITL (black arrows) (A). In addition, these aggregates of medium-sized ROQUIN-positive cells (brown, granular staining) co expressed the T_{FH} -associated marker PD1 (red, membrane staining) (B). Double immunohistochemistry, original magnification $\times 250$. doi:10.1371/journal.pone.0064536.g003

Twelve AITL tumor frozen tissue samples were selected on the basis of high tumor cell content. After complete immunostaining for T_{FH} markers including PD1, ICOS and CXCL13, a semi-quantitative evaluation of tumor cells was performed as previously described [21] and cases with more than 50% tumor cells were selected for *ROQUIN* sequence analyses (Figure 1).

Immunohistochemistry

For *in situ* evaluation of *ROQUIN* expression, deparaffinised tissue sections of 8 AITL samples were stained with a polyclonal antibody (Novius biologicals NBP1-89590, Cambridge, United Kingdom) using a Vectastain immunoperoxidase method (Vector Labs, Peterborough, UK) and revealed with Diaminobenzidine (DAB). Specificity of the antibody was validated using NIH3T3 transfected with human full length *ROQUIN* cDNA (data not shown). The distribution and phenotypic characteristics of *ROQUIN*-positive cells *in vivo* was explored by double immunostainings for *ROQUIN* and either PAX5 (as a B-cell marker) and PD1 (as T_{FH} marker). Briefly, cases were first stained for *ROQUIN* using an immunoperoxidase method (Vectastain), then for PAX5 (DakoCytomation, Glostrup, Denmark) or PD1




Figure 4. Expression of ICOS and miR101 expression in human reactive and neoplastic T_{FH} cells. Analyses of ICOS expression (210439_at). The level of ICOS mRNA expression is maintained even in the presence of *ROQUIN* transcripts both in human reactive and tumor T_{FH} cells (A) Level of miR101 (has-miR-101) is low and similar in both tumor and reactive T_{FH} cells ($p=0.8$ unpaired t-test, NS) (B). doi:10.1371/journal.pone.0064536.g004

(ABCAM, Cambridge, UK) using a Vectastain phosphatase alkaline method (Vector Labs) and revealed with Naphthol fast red. Images were captured with a Zeiss Axioskop2 microscope (Zeiss). Photographs were taken with an Olympus DP70 camera. Images were acquired with Olympus DP Controller and images were processed with Adobe Photoshop Version 7.0 (Adobe Systems).

Microarray and RT-PCR analysis

Total RNAs extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA) were used either for microarray procedures on HG-U133 plus 2.0 Affymetrix GeneChip array) as previously described [12] or for microRNA gene expression profiling on Agilent Human v3 miRNA microarray (G4471A, Agilent, Santa Clara CA). Analyses of gene expression profiles focused on probesets matching to *ROQUIN* (228996_at), *ICOS* (210439_at), and on miR101 (has-miR-101). The levels of *ROQUIN* and *ICOS* transcripts in reactive and neoplastic T_{FH} were determined by TaqMan quantitative reverse-transcriptase PCR (qRT-PCR; Applied Biosystems) on Light Cycler 480, after normalization to *HPRT* mRNA, and compared to purified reactive T_{FH}, according to the $2^{-\Delta\Delta CT}$ method.

Sequence analyses

ROQUIN cDNA was amplified by PCR in 3 fragments encompassing the coding sequence. Direct sequencing of PCR products was performed for the first two 5' fragments. A cloning phase was necessary for exons 16 to 19 sequencing due to alternative splicing. Sequences were obtained on a 3130X1 genetic analyzer (Applied biosystems) and compared with the *ROQUIN* reference sequence (GenBank accession number NM_172071) using seqscape software. PCR and sequencing primers are available upon request. It has been established that this sequencing method allows the detection of a mutated allele when it represents 10% or more of the total amplified alleles [22].

Results and Discussion

The levels of *ROQUIN* transcripts are similar in neoplastic and reactive T_{FH} cells

The analyses of *ROQUIN* probesets in our previously published transcriptomic dataset [12] disclosed the presence of *ROQUIN* transcripts in 17/17 AITL tissue samples with a slightly higher level in the two AITL cell-sorted samples enriched in tumor cells ($n=2$) (Figure 2A). However, as reactive T (CD4, CD8) and B (CD19) cell subsets also contain *ROQUIN* mRNA (Figure 2B) and

may thus compound the precise analysis of *ROQUIN* level of expression in tumor T_{FH}, we thus performed additional transcriptomic analyses of CD4⁺/CXCR5⁺/ICOS⁺ sorted T_{FH} cells obtained from reactive tonsils ($n=12$) and AITL ($n=8$) on Affymetrix microarray. Similar levels of *ROQUIN* transcripts were observed in T_{FH} purified either from reactive tonsils or from AITL lymph nodes (Figure 2C), thus excluding the hypothesis of a *ROQUIN* extinction by promoter alteration or gene expression dysregulation in AITL.

ROQUIN protein is expressed by AITL tumor cells

In situ evaluation of the pattern of *ROQUIN* expression was performed by immunohistochemistry. In all eight AITL cases investigated, numerous cells showing a granular cytoplasmic staining were observed. These comprised scattered large cells resembling B-blasts, smaller lymphocytes and many small to medium-sized atypical cells suggestive of the neoplastic cell component, as well as endothelial cells (Figure 3A). Double immunostainings performed in 4 cases demonstrated that most *ROQUIN*-positive cells were PAX5-negative and that many of them expressed PD1, therefore sharing the characteristic morphological and phenotypic features of neoplastic T_{FH} cells (Figure 3B). Furthermore, the observed granular cytoplasmic staining is compatible with Roquin localization in P bodies or stress granules as reported in the mouse [23,24].

ROQUIN coding sequence is not mutated in human AITL

We next investigated the presence of missense mutations in *ROQUIN* coding sequence. The 3402 bp *ROQUIN* coding sequence was obtained from 12 AITL samples with a high tumor load as well as normal CD4⁺ T cells sorted from 2 reactive tonsils. In contrast to Sanroque mice that develop a TFH cell lymphoproliferative disorder with several symptoms of AITL including auto-immune manifestations and organomegaly as a result of Roquin mutations [19], no mutation was found in any of the AITL patients.

ICOS and miR101 expression are similarly expressed in reactive and AITL T_{FH}

Physiologically, in mice, Roquin limits ICOS expression by promoting the degradation of *ICOS* mRNA in a dose-dependent manner [24,25]. In sanroque mice, mutated Roquin is unable to promote *ICOS* mRNA degradation, resulting in the overexpression of the protein. Here, we show that the level of *ICOS* mRNA expression is maintained even in the presence of *ROQUIN* transcripts both in human reactive and tumor T_{FH} cells

(Figure 4A). This is in accordance with the common ICOS expression by neoplastic T-cells in AITL [26,27]. It has been suggested that Roquin repressive effect on ICOS transcripts requires miR101 expression [25]. We therefore looked for miR101 expression in our T_{FH} cells. Level of miR101 was low and similar in both neoplastic and reactive T_{FH} cells (Figure 4B), in accordance with recent finding in mouse showing that BCL6 could repress inhibitors of specific T_{FH} expressing gene including miR101 [28].

Conclusion

Altogether, by comparing reactive and AITL T_{FH} cells, we have shown here that neither alteration of *ROQUIN* gene nor deregulation of miR101 expression is likely to be a frequent recurrent abnormality in AITL. Expanding knowledge on the pathways deregulated by *Roquin* mutation in Sanroque mice might

uncover other molecules of potential relevance to AITL pathophysiology.

Acknowledgments

The authors wish to thank Dr Launey for providing children tonsils and Virginie Fataccioli for her contribution. We are also thankful for the contribution made by Christelle Thibault from the IGBMC platform (Affymetrix, Philippe Kastner, Strasbourg) and Philippe Dessen from Agilent miRNA platform, Institut Gustave Roussy.

Author Contributions

Conceived and designed the experiments: MHDL TA MT LdL AdR KT PA. Performed the experiments: TA MT LdL AdR KT PA CA NM. Analyzed the data: TA MHDL MT AdR NM PG. Contributed reagents/materials/analysis tools: KT PA AdR. Wrote the paper: MHDL TA PG LdL.

References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press.
2. Frizzera G, Moran EM, Rappaport H (1974) Angio-immunoblastic lymphadenopathy with dysproteinemia. *Lancet* 1(7866): 1070–3.
3. Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, et al. (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. *Blood* 111(9): 4463–70.
4. Theodorou I, Bigorne C, Delfau MH, Lahet C, Cochet G, et al. (1996) VJ rearrangements of the TCR gamma locus in peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturing gradient gel electrophoresis. *J Pathol* 178(3): 303–10.
5. Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, et al. (2007) Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98–3936. *Leukemia* 21(2): 215–21.
6. de Leval L, Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. *British Journal of Haematology* 148(5): 673–89.
7. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, et al. (2012) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood* 119(8): 1901–3.
8. Lemonnier F, Couronné L, Parrens M, Jaïs J-P, Travert M, et al. (2012) Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood* 120(7): 1466–9.
9. Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, et al. (2006) Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. *Am J Surg Pathol* 30(4): 490–4.
10. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, et al. (2005) Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? *Blood* 106(4): 1501–2.
11. Krenacs L, Schaeferli P, Kis G, Bagdi E (2006) Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. *Blood* 108(3): 1110–1111.
12. de Leval L, Rickman DS, Thielen C, Reynies A de, Huang Y-L, et al. (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. *Blood* 109(11): 4952–63.
13. Walker LS, Gulbranson-Judge A, Flynn S, Brocker T, Lane PJ (2000) Costimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. *Immunol Today* 21(7): 333–7.
14. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, et al. (2009) Bcl6 mediates the development of T follicular helper cells. *Science* 325(5943): 1001–5.
15. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, et al. (2009) Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science* 325(5943): 1006–10.
16. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, et al. (2004) T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. *J Immunol* 173(1): 68–78.
17. Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, et al. (2004) Unique gene expression program of human germinal center T helper cells. *Blood* 104(7): 1952–60.
18. Moser B, Schaeferli P, Loetscher P. (2002) CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. *Trends Immunol* 23(5): 250–4.
19. Ellyard JI, Chia T, Rodriguez-Pinilla S-M, Martin JL, Hu X, et al. (2012) Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. *Blood* 120(4): 812–21.
20. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, et al. (2005) A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. *Nature* 435(7041): 452–8.
21. Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Chailane D, et al. (2012) Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. *Haematologica* 97(10): 1594–602.
22. Chaligné R, James C, Tonetti C, Besancenot R, Le Couédic JP, et al. (2007) Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. *Blood* 110(10): 3735–43.
23. Athanasopoulos V, Barker A, Yu D, Tan AH, Srivastava M, et al. (2010) The ROQUIN family of proteins localizes to stress granules via the ROQ domain and binds target mRNAs. *FEBS J* 277(9): 2109–27.
24. Glasmacher E, Hoefig KP, Vogel KU, Rath N, Du L, et al. (2010) Roquin binds inducible costimulator mRNA and effectors of mRNA decay to induce microRNA-independent post-transcriptional repression. *Nat Immunol* 11(8): 725–33.
25. Yu D, Tan AH-M, Hu X, Athanasopoulos V, Simpson N, et al. (2007) Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. *Nature* 450(7167): 299–303.
26. Marafioti T, Paterson JC, Ballabio E, Chott A, Natkunam Y, et al. (2010) The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. *Haematologica* 95(3): 432–9.
27. Baseggio L, Traverse-Glehen A, Berger F, French M, Jallades L, et al. (2011) CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. *Mod Pathol* 24(7): 993–1003.
28. Yu D, Rao S, Tsai LM, Lee SK, He Y, et al. (2009) The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. *Immunity* 31(3): 457–68.